Bleeding disorders such as hemophilia are chronic disorders characterized by bleeding episodes that may occur spontaneously or after mild to severe trauma. The timing and severity of bleeding episodes are unpredictable, even for patients on…
Although the vast majority of individuals in the United States with hemophilia A and B are now using recombinant clotting factor concentrates, there are still many individuals with hemophilia A and B and von Willebrand disease who rely on…
Pursuant to a currently unsubstantiated report of possible classic CJD related to the recent death of a person with hemophilia who developed dementia, and in conjunction with recommendations 1 and 2 in the MASAC Consensus Statement on Plasma Safety…
Revisions: 176
Radionuclide synovectomy (RS) utilizing phosphorous 32-sulfur colloid (P32) has been performed in Canada since 1977 and in the United States since 1988 for rheumatoid arthritis. (1) In individuals with hemophilia and chronic…
Since the advent of the AIDS epidemic in 1982, when it was recognized that one of the groups at high risk of contracting HIV was men who had sex with men (MSM), MSM have been permanently deferred from donating blood in the US. Recently the Gay Men's…
The Nursing Working Group conducted a survey of use of Emergency Medical Identification (EMI) devices available for children and found that there are no devices appropriate for infants and young children under 3 years of age. In addition, the number…
Revisions: 174
Rare plasma protein coagulation disorders may result in a hemorrhagic or a thrombotic tendency based upon the specific coagulation factor affected and the associated level of deficiency. The treatment advances achieved for…
In January, 2011, NHF issued a Medical Advisory (#412) about a recall of non-sterile alcohol prep pads produced by one company, Triad, due to reports of serious infections with their use.(1) In March, 2011, the CDC reported on 2 children who had…
Hemophilia A and B meet criteria for rare disorders because they occur in less than 1 in 200,000 individuals. Development of new medications for rare disorders is costly for manufacturers, who have no assurance that they will recover their costs…
Treatment for hemophilia A and B involves the administration of clotting factor concentrates that are safe and effective, but unfortunately they are expensive life-long therapies, especially for patients with severe disease who must receive…